Precision Care

Dynamic Disease Management of
Autoimmune & Inflammatory Diseases

Using RNA Analytics, Bioinformatics, and Machine Learning/AI

AMPEL Genomic Platform (AGP®) supports
genomic blood and biopsy tests for patients:

Identify molecular pathways

Evaluate immune status

Predict flares & drug options

RNA-Based Precision Medicine

One Platform, Many Solutions

Key Stats


coverage of all known genes and is disease agnostic

autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus

technology patents filed & pending with the freedom to operate

pharma customers validate the technology

additional autoimmunity products in development

Featured News

About the Founders

AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs. Their success has been a combination of world-class science with business acumen. In 2023, AMPEL was recognized as Virginia’s Innovator-of-the-Year by CBIC.  Last year, the Coalition of 21st Century Precision Medicine elected AMPEL to membership.  Earlier this year, AMPEL was ranked by Nature in the top Precision Medicine Companies with respect to the impact of published science (Foundation Medicine, Illumina, Tempus, ThermoFischer, AMPEL BioSolutions, Guardant Health, AdaptiveTechnologies) and received a Virginia Catalyst Award

Precision Medicine

Powered by research and analytics, we use genomic data to reduce uncertainty from clinical care.

Pin It on Pinterest